JP2021513328A - 抗ｍｓ４ａ６ａ抗体及びその使用方法 - Google Patents

抗ｍｓ４ａ６ａ抗体及びその使用方法 Download PDF

Info

Publication number
JP2021513328A
JP2021513328A JP2020541758A JP2020541758A JP2021513328A JP 2021513328 A JP2021513328 A JP 2021513328A JP 2020541758 A JP2020541758 A JP 2020541758A JP 2020541758 A JP2020541758 A JP 2020541758A JP 2021513328 A JP2021513328 A JP 2021513328A
Authority
JP
Japan
Prior art keywords
antibody
ms4a6a
amino acid
disease
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020541758A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2019152706A5 (https=
JP2021513328A5 (https=
Inventor
フィリップ コング
フィリップ コング
ハーブ リン
ハーブ リン
ティナ シュワーブ
ティナ シュワーブ
アンジー イー
アンジー イー
アーノン ローゼンタール
アーノン ローゼンタール
Original Assignee
アレクター リミテッド ライアビリティ カンパニー
アレクター リミテッド ライアビリティ カンパニー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アレクター リミテッド ライアビリティ カンパニー, アレクター リミテッド ライアビリティ カンパニー filed Critical アレクター リミテッド ライアビリティ カンパニー
Publication of JP2021513328A publication Critical patent/JP2021513328A/ja
Publication of JPWO2019152706A5 publication Critical patent/JPWO2019152706A5/ja
Publication of JP2021513328A5 publication Critical patent/JP2021513328A5/ja
Priority to JP2023095282A priority Critical patent/JP2023113896A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2020541758A 2018-01-31 2019-01-31 抗ｍｓ４ａ６ａ抗体及びその使用方法 Pending JP2021513328A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023095282A JP2023113896A (ja) 2018-01-31 2023-06-09 抗ｍｓ４ａ６ａ抗体及びその使用方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862624578P 2018-01-31 2018-01-31
US62/624,578 2018-01-31
US201862646846P 2018-03-22 2018-03-22
US62/646,846 2018-03-22
PCT/US2019/016141 WO2019152706A1 (en) 2018-01-31 2019-01-31 Anti-ms4a6a antibodies and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023095282A Division JP2023113896A (ja) 2018-01-31 2023-06-09 抗ｍｓ４ａ６ａ抗体及びその使用方法

Publications (3)

Publication Number Publication Date
JP2021513328A true JP2021513328A (ja) 2021-05-27
JPWO2019152706A5 JPWO2019152706A5 (https=) 2022-02-07
JP2021513328A5 JP2021513328A5 (https=) 2022-02-07

Family

ID=67479397

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020541758A Pending JP2021513328A (ja) 2018-01-31 2019-01-31 抗ｍｓ４ａ６ａ抗体及びその使用方法
JP2023095282A Pending JP2023113896A (ja) 2018-01-31 2023-06-09 抗ｍｓ４ａ６ａ抗体及びその使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023095282A Pending JP2023113896A (ja) 2018-01-31 2023-06-09 抗ｍｓ４ａ６ａ抗体及びその使用方法

Country Status (5)

Country Link
US (2) US20210122817A1 (https=)
EP (1) EP3746484A4 (https=)
JP (2) JP2021513328A (https=)
CN (1) CN112204050B (https=)
WO (1) WO2019152706A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112204050B (zh) 2018-01-31 2025-03-14 艾莱克特有限责任公司 抗ms4a6a抗体及其使用方法
CN111971301B (zh) 2018-01-31 2025-01-07 艾莱克特有限责任公司 抗ms4a4a抗体及其使用方法
MX2022001260A (es) 2019-07-31 2022-04-18 Alector Llc Anticuerpos anti-ms4a4a y metodos de uso de los mismos.
CN115029383B (zh) * 2022-04-21 2024-02-20 苏天生命科技(苏州)有限公司 Ms4a3蛋白在调控红细胞成熟中的应用
CN116219009B (zh) * 2022-10-19 2024-10-01 杭州师范大学 小胶质细胞特异性表达的ms4a6a在胶质母细胞瘤治疗或预后评估试剂盒上的应用
US20250134920A1 (en) 2023-10-30 2025-05-01 Regeneron Pharmaceuticals, Inc. Treatment Of Myeloid Cell Dysfunction With Membrane Spanning 4-Domains A6A (MS4A6A) Inhibitors

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008506637A (ja) * 2004-06-14 2008-03-06 ザ・ボード・オブ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・イリノイ 胎児起源の細胞に対する抗体
JP2013534411A (ja) * 2010-05-25 2013-09-05 サノフイ 疼痛に関与する化合物の同定に関する方法および使用、ならびに痛覚過敏の診断方法
CN105969901A (zh) * 2016-07-27 2016-09-28 北京泱深生物信息技术有限公司 Ms4a6a作为多发性骨髓瘤诊治标志物的用途

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002251692A1 (en) 2000-12-08 2002-08-19 Duke University Identification of novel ms4a gene family members expressed by hematopoietic cells
GB0125338D0 (en) 2001-10-22 2001-12-12 Isis Innovation Process for reducing immunogenic reactions using selective TH1 cell binding antibodies
GB0324888D0 (en) 2003-10-24 2003-11-26 Novartis Ag Organic compounds
CN101001879A (zh) 2004-06-14 2007-07-18 伊利诺伊大学董事会 与胎儿而非成体cd34+/cd36+细胞结合的抗体
GB0624500D0 (en) 2006-12-07 2007-01-17 Istituto Superiore Di Sanito A novel passive vaccine for candida infections
EP2108701A1 (en) 2008-04-10 2009-10-14 Ganymed Pharmaceuticals AG Methods involving MS4A12 and agents targeting MS4A12 for therapy, diagnosis and testing
CN104774264B (zh) * 2014-01-15 2018-09-14 上海易乐生物技术有限公司 抗人proBDNF单克隆抗体及其在疼痛中的作用
CA2874083C (en) 2014-12-05 2024-01-02 Universite Laval Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases
US20190321443A1 (en) * 2016-02-16 2019-10-24 President And Fellows Of Harvard College Modulators of MS4A activity
CN105759057A (zh) * 2016-04-12 2016-07-13 上海凯璟生物科技有限公司 一种检测阿尔兹海默综合症ms4a6a的干式免疫荧光试剂盒和制备方法
CN112204050B (zh) 2018-01-31 2025-03-14 艾莱克特有限责任公司 抗ms4a6a抗体及其使用方法
CN111971301B (zh) 2018-01-31 2025-01-07 艾莱克特有限责任公司 抗ms4a4a抗体及其使用方法
MA54880A (fr) 2019-02-01 2021-12-08 Avrobio Inc Compositions et procédés de traitement de troubles neurocognitifs
MX2022001260A (es) 2019-07-31 2022-04-18 Alector Llc Anticuerpos anti-ms4a4a y metodos de uso de los mismos.
MX2022004678A (es) 2019-10-22 2022-08-15 Biogen Ma Inc Anticuerpo anti-beta amiloide para el tratamiento de la enfermedad de alzheimer.
WO2024086796A1 (en) 2022-10-20 2024-04-25 Alector Llc Anti-ms4a4a antibodies with amyloid-beta therapies

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008506637A (ja) * 2004-06-14 2008-03-06 ザ・ボード・オブ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・イリノイ 胎児起源の細胞に対する抗体
JP2013534411A (ja) * 2010-05-25 2013-09-05 サノフイ 疼痛に関与する化合物の同定に関する方法および使用、ならびに痛覚過敏の診断方法
CN105969901A (zh) * 2016-07-27 2016-09-28 北京泱深生物信息技术有限公司 Ms4a6a作为多发性骨髓瘤诊治标志物的用途

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
"抗体医薬の現状と課題", 科学技術動向, vol. 10月号, JPN6022055226, 2009, pages 13 - 25, ISSN: 0005130153 *

Also Published As

Publication number Publication date
WO2019152706A1 (en) 2019-08-08
US20210122817A1 (en) 2021-04-29
EP3746484A4 (en) 2021-11-17
US12215149B2 (en) 2025-02-04
CN112204050B (zh) 2025-03-14
US20220380455A1 (en) 2022-12-01
CN112204050A (zh) 2021-01-08
JP2023113896A (ja) 2023-08-16
EP3746484A1 (en) 2020-12-09

Similar Documents

Publication Publication Date Title
JP7486636B2 (ja) 抗ｍｓ４ａ４ａ抗体及びその使用方法
US12215149B2 (en) Anti-MS4A6A antibodies and methods of use thereof
JP7612658B2 (ja) 抗ｍｓ４ａ４ａ抗体、及びその使用方法
KR20210015872A (ko) 항-sirpa 항체 및 그의 사용 방법
JP2023519962A (ja) 抗ｍｅｒｔｋ抗体及びその使用方法
CN112912144A (zh) 抗cd33抗体及其使用方法
JP2021508498A (ja) 抗ｔｍｅｍ１０６ｂ抗体及びその使用方法
WO2023010076A1 (en) Anti-sirp-alpha antibodies and methods of use thereof
HK40036037A (en) Anti-ms4a6a antibodies and methods of use thereof
HK40034438A (zh) 抗ms4a4a抗体及其使用方法
HK40059921A (zh) 抗cd33抗体及其使用方法
HK40063237A (en) Anti-ms4a4a antibodies and methods of use thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201026

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201005

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20210222

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220128

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220128

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221227

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230307

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230816